| 000 | 01675cam a2200337 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030443.0 | ||
| 008 | 110827s2011 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.08.10.M.Sc.2011.Ib.P | ||
| 100 | 0 | _aIbrahim Mohammed Ahmed Abdulwahid Alsharabi | |
| 245 | 1 | 2 |
_aA Pharmaceutical study on certain aminosalicylates / _cIbrahim Mohammed Ahmed Abdulwahid Alsharabi ; Supervised Ahmed Abdelbary Abdelrahman , Ahmed A. Aboelwafa |
| 246 | 1 | 5 | _aدراسة صيدلية على بعض الامينوساليسلات |
| 260 |
_aCairo : _bIbrahim Mohammed Ahmed Abdulwahid Alsharabi , _c2011 |
||
| 300 |
_a177 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Industrial Pharmacy | ||
| 520 | _aThe recommended first - line therapy for the treatment of active symptoms induction of remission and maintenance of remission in patients with mild - to moderate ulcerative colitis (UC) is the anti inflammatory agent 5 - aminosalicylic acid (5- ASA or mesalazine ) . 5- ASA acts topically on the colonic mucosa but when orally administered it is extensively and rapidly absorbed in the small intestine | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aColonic targeting | |
| 653 | 4 | _aMesalazine | |
| 653 | 4 | _aUlcerative colitis | |
| 700 | 0 |
_aAhmed Abdelbary Abdelrahman , _eSupervisor |
|
| 700 | 0 |
_aAhmed Abdelfatah Aboelwafa , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c35002 _d35002 |
||